Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 8,81 € (+1298,41%). La mediana è 9,11 € (+1346,03%).
| Acquista |
18 |
| Mantieni |
1 |
| Vendi |
0 |
Discussioni nella community
Non ci sono ancora discussioni su questo asset.
Avvia discussioneNotizie Vai al feed delle notizie
Aldeyra adds Darlene Deptula-Hicks to board of directors
Aldeyra has appointed Darlene Deptula-Hicks to its board of directors; she brings more than 30 years of experience in the biotech sector and expertise as a finance executive at public and private life-science companies. Deptula-Hicks is currently interim CFO of Normunity and was previously CFO of F-star Therapeutics; her experience with IPOs, capital raising and M&A is expected to support potential commercialization of Aldeyra’s therapies. Aldeyra is developing RASP modulators and is advancing reproxalap and ADX-2191 in late-stage development; the company has a market capitalization of $104 million, a current ratio of 2.72, and its stock has traded well below last year’s level since the start of the year, while analyst price targets remain between $2 and $13. » Altro su de.investing.com
Aldeyra Therapeutics repays $15 million loan and terminates credit facility
Aldeyra Therapeutics repaid all outstanding liabilities of $15 million on April 1, thereby terminating the loan agreement with Hercules Capital in accordance with the contract. The company reports a balance sheet with more cash than debt and expects that cash, cash equivalents and marketable securities will fund operations through 2028. At the same time, Aldeyra faces regulatory pressure following an FDA Complete Response Letter for Reproxalap; analyst reactions are mixed (BTIG: buy, price target $9.00; H.C. Wainwright: neutral, price target $2.00). The stock trades well below last year’s level, reflecting the ongoing uncertainties. » Altro su de.investing.com
Aldeyra Therapeutics: chief development officer Dr. Stephen G. Machatha to resign by March 2026
Aldeyra Therapeutics announced that Dr. Stephen G. Machatha has voluntarily resigned as chief development officer; his last day will be no later than March 31, 2026. The company and Machatha reached a transition agreement under which he will remain employed through his departure, continue to receive his base salary and benefits, and have outstanding equity awards remain unchanged. As part of the agreement, Machatha will receive a one‑time payment of $88,000 and may receive an additional $88,000 if he signs further release agreements after leaving. The company emphasized that the resignation is not the result of any disagreement with management or the board. » Altro su de.investing.com
Aldeyra receives EMA orphan drug status for ADX-2191 to treat rare retinal diseases
Aldeyra Therapeutics has been granted orphan drug status by the European Medicines Agency for ADX-2191 for the treatment of inherited retinal dystrophies, including retinitis pigmentosa. The company will benefit from regulatory advantages and plans to conduct further clinical trials, while its financial position is described as solid. Additionally, progress has been reported in the development and approval applications of other medications. » Altro su de.investing.com
Aldeyra receives positive FDA feedback for eye drug Reproxalap
Aldeyra Therapeutics has announced that the US Food and Drug Administration (FDA) has accepted the resubmitted approval application for its eye drug Reproxalap, intended for the treatment of dry eye disease. The FDA's decision is expected by December 16, 2025, following the submission of additional clinical data. Analysts remain optimistic about the stock, and the company is financially well positioned to continue its development programs. » Altro su de.investing.com
Dati finanziari dell'azienda
| (EUR) | settembre 2026 | YoY |
|---|---|---|
| Ricavi | 0 | - |
| Utile lordo | 0 | - |
| Utile netto | -3,32 Mln | 49,29% |
| EBITDA | -3,19 Mln | 47,71% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 38,23 Mln € |
Numero di azioni | 60,36 Mln |
Massimo/minimo a 52 settimane | 5,40 € - 0,48 € |
| Dividendi | No |
Beta | 1,29 |
Rapporto P/E | -2,18 |
Rapporto PEG | -0,02 |
Rapporto P/B | 0,00 |
Rapporto P/S | 0,00 |
Profilo aziendale
Aldeyra Therapeutics, Inc., una società biotecnologica, sviluppa e commercializza farmaci per malattie oculari e sistemiche a base immunomediata. Il principale candidato farmaco dell'azienda è reproxalap, un modulatore di specie aldeidiche reattive (RASP), che si trova in fase III di sperimentazione clinica per il trattamento delle malattie dell'occhio secco e della congiuntivite allergica. L'azienda sviluppa inoltre ADX-629, un modulatore RASP di prima classe somministrato per via orale, in fase II di sperimentazione clinica per la psoriasi, l'asma e il COVID-19; e ADX-2191, un inibitore della diidrofolato reduttasi, in fase III per la prevenzione della vitreoretinopatia proliferativa e in fase II di sperimentazione clinica per il trattamento della retinite pigmentosa, nonché per il trattamento del linfoma vitreoretinico primario. L'azienda ha un accordo di licenza con Madrigal Pharmaceuticals, Inc. per lo sviluppo di ADX-1612, che inibisce la proteina chaperome per il trattamento delle malattie infiammatorie. La società era precedentemente nota come Aldexa Therapeutics, Inc. e ha cambiato denominazione in Aldeyra Therapeutics, Inc. nel marzo 2014. Aldeyra Therapeutics, Inc. è stata costituita nel 2004 e ha sede a Lexington, nel Massachusetts.
| Nome | Aldeyra Therapeutics |
| CEO | Todd C. Brady |
| Sede centrale | Lexington,
ma Stati Uniti |
| Sito web | |
| Settore | Sanità |
| Industria | Biotecnologia |
| Quotazione in borsa | 02/05/2014 |
| Dipendenti | 6 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
NASDAQ | ALDX |
Frankfurt | 137.F |
Düsseldorf | 137.DU |
München | 137.MU |